Efficacy and tolerability of PCSK9 inhibitors in real-world clinical practice

TY - JOUR

T1 - Efficacy and tolerability of PCSK9 inhibitors in real-world clinical practice

AU - Devaiah, Prashasthi

AU - Handjiev, Sava

AU - George, Jacob

PY - 2023/11/29

Y1 - 2023/11/29

N2 - Despite widespread use of statins and other lipid-lowering therapies for hypercholesterolaemia, cardiovascular (CV) mortality and morbidity remains high. The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, have been approved for use in patients with familial hypercholesterolaemia and high CV risk in the UK. We reviewed the records of patients at a large health board in Scotland, who were prescribed these agents, to determine their real-world efficacy and tolerability in routine clinical care.

AB - Despite widespread use of statins and other lipid-lowering therapies for hypercholesterolaemia, cardiovascular (CV) mortality and morbidity remains high. The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, have been approved for use in patients with familial hypercholesterolaemia and high CV risk in the UK. We reviewed the records of patients at a large health board in Scotland, who were prescribed these agents, to determine their real-world efficacy and tolerability in routine clinical care.

U2 - 10.5837/bjc.2023.044

DO - 10.5837/bjc.2023.044

M3 - Article

C2 - 39247417

SN - 0969-6113

VL - 30

SP - 153

EP - 156

JO - British Journal of Cardiology

JF - British Journal of Cardiology

ER -